Acetazolamide interactions
Full monograph for AcetazolamideCheck it against another medicine
Medicines
381 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloride | Major | Synergy | Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or… | 5 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Since hypokalemia and hypomagnesemia are known risk factors for… | 2 sources — open the full entry |
| Aspirin | Major | Distribution | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Aspirin + Dipyridamole | Major | Distribution | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Major | Others · Synergy | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate…2 documented mechanisms | 24 sources — open the full entry |
| Bismuth Subsalicylate | Major | Distribution | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Major | Distribution | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Clopidogrel + Aspirin | Major | Distribution · Unknown | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate…2 documented mechanisms | 16 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Dithranol + Boric Acid + Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Empagliflozin + Metformin Hydrochloride | Major | Antagonism · Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase…2 documented mechanisms | 114 sources — open the full entry |
| Glimepiride + Metformin | Major | Antagonism · Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase…2 documented mechanisms | 114 sources — open the full entry |
| Glipizide + Metformin Hydrochloride | Major | Antagonism · Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase…2 documented mechanisms | 114 sources — open the full entry |
| Linagliptin + Metformin Hydrochloride | Major | Antagonism · Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase…2 documented mechanisms | 114 sources — open the full entry |
| Malic Acid + Benzoic acid + Salicylic acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Metformin Hydrochloride | Major | Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase… | 19 sources — open the full entry |
| Monobasic Sodium Phosphate + Dibasic Sodium Phosphate | Major | Others | The following interaction applies only to products containing sodium biphosphate that are used for bowel cleansing. It does not apply to products containing… | 3 sources — open the full entry |
| Mucopolysaccharide Polysulphate + Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Pioglitazone + Metformin Hydrochloride | Major | Antagonism · Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase…2 documented mechanisms | 114 sources — open the full entry |
| Rhubarb Extract + Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Salicylic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Salicylic Acid + Lactic Acid | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Salicylic acid + Zinc Pyrithione | Major | Others | The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate… | 16 sources — open the full entry |
| Sitagliptin + Metformin Hydrochloride | Major | Antagonism · Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase…2 documented mechanisms | 114 sources — open the full entry |
| Topiramate | Major | Synergy | Concomitant use of carbonic anhydrase inhibitors such as acetazolamide, topiramate, and zonisamide with each other or with other carbonic anhydrase inhibitors… | 7 sources — open the full entry |
| Vildagliptin + Metformin Hydrochloride | Major | Synergy | Coadministration with carbonic anhydrase inhibitors may potentiate the risk of lactic acidosis associated with the use of metformin. Carbonic anhydrase… | 19 sources — open the full entry |
| Ziprasidone | Major | Synergy | Ziprasidone can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of ziprasidone and agents that can… | 5 sources — open the full entry |
| Zonisamide | Major | Synergy | Concomitant use of carbonic anhydrase inhibitors such as acetazolamide, topiramate, and zonisamide with each other or with other carbonic anhydrase inhibitors… | 7 sources — open the full entry |
| Acarbose | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Aclidinium Bromide + Formoterol Fumarate | Moderate | Synergy | Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically… | 8 sources — open the full entry |
| Acyclovir + Hydrocortisone | Moderate | Synergy · Unknown | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result…2 documented mechanisms | 8 sources — open the full entry |
| Alogliptin Benzoate | Moderate | Antagonism | The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics… | 95 sources — open the full entry |
| Alprazolam | Moderate | Antagonism | Benzodiazepines may counteract the beneficial effects of acetazolamide in preventing altitude sickness by inhibiting respiratory responses to hypoxia. | 8 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide | Moderate | Synergy | The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes… | 5 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethicone | Moderate | Synergy | The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes… | 5 sources — open the full entry |
| Amisulpride | Moderate | Synergy | Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce… | 2 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Antagonism · Excretion | Benzodiazepines may counteract the beneficial effects of acetazolamide in preventing altitude sickness by inhibiting respiratory responses to hypoxia.2 documented mechanisms | 9 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy · Unknown | Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects…2 documented mechanisms | 26 sources — open the full entry |
| Amphotericin B | Moderate | Synergy | The concomitant use of amphotericin and potassium-wasting diuretics may result in increased risk of hypokalemia due to additive effects. | 1 sources — open the full entry |
| Arformoterol Tartrate | Moderate | Synergy | Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically… | 8 sources — open the full entry |
| Atracurium Besilate | Moderate | Synergy | Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants. | 4 sources — open the full entry |
| Avanafil | Moderate | Synergy | Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated… | 4 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result…2 documented mechanisms | 16 sources — open the full entry |
| Beclomethasone Dipropionate (Inhaler) | Moderate | Synergy | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result… | 8 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy · Unknown | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result…2 documented mechanisms | 8 sources — open the full entry |
| Beclomethasone Dipropionate + Formoterol Fumarate | Moderate | Synergy | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result…2 documented mechanisms | 16 sources — open the full entry |
| Betamethasone | Moderate | Synergy | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result… | 8 sources — open the full entry |
| Betamethasone + Calcipotriol | Moderate | Synergy | The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result… | 8 sources — open the full entry |
Conditions
Conditions in which Acetazolamide needs care, as documented in this source.
Adrenal Insufficiency
MajorThe use of carbonic anhydrase inhibitors is contraindicated in patients with adrenal insufficiency. The carbonic anhydrase inhibitor effect may exacerbate electrolyte problems that can occur with primary adrenal insufficiency. Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered to these patients. Monitoring electrolyte levels is recommended.
2 sources
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Bone Marrow Failure Disorders
MajorThe use of carbonic anhydrase inhibitors may rarely cause bone marrow suppression and blood dyscrasias at recommended dosages. Aplastic anemia, thrombocytopenia or thrombocytopenia purpura, leukopenia, agranulocytosis, and hemolytic anemia have been reported. Extreme caution should be exercised if carbonic anhydrase inhibitors are administered to patients with these preexisting conditions. A baseline CBC and platelet count is recommended, as well as monitoring at regular intervals during therapy.
12 sources
- Keisu M, Wiholm BE, Ost A, Mortimer O "Acetazolamide-associated aplastic anaemia." J Intern Med 228 (1990): 627-32
- Gangitano JL, Foster SH, Contro RM "Nonfatal methazolamide-induced aplastic anemia." Am J Ophthalmol 86 (1978): 138-9
- Wisch N, Fischbein FI, Siegel R, Glass JL, Leopold I "Aplastic anemia resulting from the use of carbonic anhydrase inhibitors." Am J Ophthalmol 75 (1973): 130-2
- Lubeck MJ "Aplastic anemia following acetazolamide therapy." Am J Ophthalmol 69 (1970): 684-5
- Kristinsson A "Fatal reaction to acetazolamide." Br J Ophthalmol 51 (1967): 348-9
- Englund GW "Fatal pancytopenia and acetazolamide therapy." JAMA 210 (1969): 2282
- Rentiers PK, Johnston AC, Buskard N "Severe aplastic anemia as a complication of acetazolamide therapy." Can J Ophthalmol 5 (1970): 337-42
- McWhae JA, Chang J, Lipton JH "Drug-induced fatal aplastic anemia following cataract surgery." Can J Ophthalmol 27 (1992): 313-5
Show all 12 sourcesShow fewer sources
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Glaucoma, Angle-Closure
MajorThe use of carbonic anhydrase inhibitors is contraindicated in patients with closed-angle glaucoma. Carbonic anhydrase inhibitors may mask worsening glaucoma due to decreased intraocular pressure. Extreme caution should be exercised if carbonic anhydrase inhibitors is administered to these patients.
3 sources
- Fan JT, Johnson DH, Burk RR "Transient myopia, angle-closure glaucoma, and choroidal detachment after oral acetazolamide." Am J Ophthalmol 115 (1993): 813-4
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Hypokalemia
MajorThe use of carbonic anhydrase inhibitors is contraindicated in patients with hypokalemia . Carbonic anhydrase inhibitors may cause increased potassium excretion. Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.
3 sources
- Torres CF, Griggs RC, Moxley RT, Bender AN "Hypokalemic periodic paralysis exacerbated by acetazolamide." Neurology 31 (1981): 1423-8
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Hyponatremia
MajorThe use of carbonic anhydrase inhibitors is contraindicated in patients with hyponatremia . Carbonic anhydrase inhibitors may cause sodium excretion. Extreme caution should be exercised if a carbonic anhydrase inhibitor is administered and monitoring electrolyte levels is recommended.
2 sources
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Kidney Diseases
MajorThe use of some carbonic anhydrase inhibitors is contraindicated in patients with severe kidney disease. Dysuria, crystalluria, renal colic, and other renal lesions have been reported during therapy with carbonic anhydrase inhibitors.
12 sources
- Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991): 457-64
- Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982): 1114
- Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982): 422
- Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981): 1527-8
- De Marchi S, Cecchin E "Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis." Clin Sci 78 (1990): 295-302
- Korzets A, Gafter U, Floru S, Chagnac A, Zevin D "Deteriorating renal function with acetazolamide in a renal transplant patient with pseudotumor cerebri." Am J Kidney Dis 21 (1993): 322-4
- Parfitt AM "Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis: relationship to citrate and calcium excretion." Arch Intern Med 124 (1969): 736-40
- Tawil R, Moxley RT 3d, Griggs RC "Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders." Neurology 43 (1993): 1105-6
Show all 12 sourcesShow fewer sources
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- Parikh JR, Nolan RL, Bannerjee A, Gault MH "Acetazolamide-associated nephrocalcinosis in a transplant kidney." Transplantation 59 (1995): 1742-3
- Schwenk MH, Stpeter WL, Meese MG, Singhal PC "Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis." Pharmacotherapy 15 (1995): 522-7
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Liver Failure
MajorThe use of carbonic anhydrase inhibitors is contraindicated in patients with marked liver disease or cirrhosis. Carbonic anhydrase inhibitors increase the risk of developing hepatic encephalopathy in these patients. Extreme caution should be exercised if carbonic anhydrase inhibitors are administered in patients with mild to moderate liver disease as the clearance of the drug can be decreased. A dose reduction might be needed and monitoring of the liver function is recommended.
6 sources
- Maren TH "Acetazolamide and advanced liver disease ." Am J Ophthalmol 102 (1986): 672-3
- Margo CE "Acetazolamide and advanced liver disease." Am J Ophthalmol 101 (1986): 611-2
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Acidosis
ModerateReduced plasma bicarbonate levels and, in some instances, elevated plasma chloride levels may result in metabolic acidosis during long-term therapy with carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with metabolic or hyperchloremic acidosis or with conditions that predispose to acidosis (renal disease, severe respiratory disorders, diarrhea). The measurement of baseline and periodic serum bicarbonate is recommended. If metabolic acidosis develops (it may be corrected by administration of sodium bicarbonate), and persists, a dose reduction or treatment discontinuation should be considered.
10 sources
- Reid W, Harrower AD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982): 1114
- Goodfield M, Davis J, Jeffcoate W "Acetazolamide and symptomatic metabolic acidosis in mild renal failure ." Br Med J (Clin Res Ed) 284 (1982): 422
- Maisey DN, Brown RD "Acetazolamide and symptomatic metabolic acidosis in mild renal failure." Br Med J (Clin Res Ed) 283 (1981): 1527-8
- Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63
- Heller I, Halevy J, Cohen S, Theodor E "Significant metabolic acidosis induced by acetazolamide: not a rare complication." Arch Intern Med 145 (1985): 1815-7
- Gabay EL "Metabolic acidosis from acetazolamide therapy ." Arch Ophthalmol 101 (1983): 303-4
- Berthelsen P "Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis." Intensive Care Med 8 (1982): 269-74
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
Show all 10 sourcesShow fewer sources
- "Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals (2001):
Acidosis, Respiratory
ModerateCarbonic anhydrase inhibitors may exacerbate pulmonary disease in patients with elevated pCO2 levels. Respiratory acidosis may be precipitated or increased in these patients. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with respiratory acidosis, and conditions where alveolar ventilation may be impaired (pulmonary obstruction, emphysema, etc) and can precipitate or aggravate acidosis. Respiratory status should be monitored during therapy.
4 sources
- Watson WA, Garrelts JC, Zinn PD, Garriott JC, McLemore TL, Clementi WA "Chronic acetazolamide intoxication." J Toxicol Clin Toxicol 22 549-63
- Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979): 284-6
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Diabetes Mellitus
ModerateElevation of blood glucose, possibly caused by hypokalemia, and glycosuria have been reported rarely in diabetics receiving carbonic anhydrase inhibitors. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with diabetes mellitus. Routine glucose monitoring is recommended during therapy.
4 sources
- Hannedouche T, Lazaro M, Delgado AG, Boitard C, Lacour B, Grunfeld JP "Feedback-mediated reduction in glomerular filtration during acetazolamide infusion in insulin-dependent diabetic patients." Clin Sci 81 (1991): 457-64
- Siklos P, Henderson RG "Severe acidosis from acetazolamide in a diabetic patient." Curr Med Res Opin 6 (1979): 284-6
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Gout
ModerateUric acid excretion is decreased during therapy with carbonic anhydrase inhibitors, and gout may be exacerbated. Therapy with carbonic anhydrase inhibitors should be administered cautiously in patients with gout. Elevated serum uric acid levels return to normal when the drug is discontinued. Monitoring of uric acid levels is recommended in these patients.
3 sources
- Ferry AP, Lichtig M "Gouty arthritis as a complication of acetazolamide (diamox) therapy for glaucoma." Can J Ophthalmol 4 (1969): 145-7
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Neptazane (methazolamide)." Wyeth-Ayerst Laboratories (2006):
Kidney Diseases
ModerateThe major route of elimination of carbonic anhydrase inhibitors is through the kidney. These drugs should be administered cautiously in patients with reduced renal function and a dose adjustment might be required depending on the level of impairment.
3 sources
- "Product Information. Diamox (acetazolamide)." Lederle Laboratories (2001):
- "Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical (2001):
- "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals (2001):
Therapeutic duplication
Drug classes that overlap with Acetazolamide, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
carbonic anhydrase inhibitor ant
The recommended maximum number of medicines in the 'carbonic anhydrase inhibitor anticonvulsants' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'carbonic anhydrase inhibitor anticonvulsants' category.
Example product in the source data (US market): Phentermine/topiramate
carbonic anhydrase inhibitor oph
The recommended maximum number of medicines in the 'carbonic anhydrase inhibitor ophthalmics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'carbonic anhydrase inhibitor ophthalmics' category.
Example product in the source data (US market): Dorzolamide/timolol (ophthalmic)
carbonic anhydrase inhibitor oph
The recommended maximum number of medicines in the 'carbonic anhydrase inhibitor ophthalmics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'carbonic anhydrase inhibitor ophthalmics' category.
Example product in the source data (US market): Simbrinza